AFP and hepatocellular carcinoma: Hong et al. reported that serum AFP levels and 18F-FDG PET positivity represent [43], in place of morphological factors, new biological criteria that can improve the risk stratification of tumor recurrence more than the MC for LDLT recipients with HCC [43–44].